Core Viewpoint - The company, Zhenbaodao, announced that its wholly-owned subsidiary, Bozhou Chinese Medicine Material Trading Center Co., Ltd., plans to acquire a 49% stake in its controlling subsidiary, Guizhou Shennong Valley, for a total price of 49 million RMB plus interest from the fund's regulatory account during the investment period [1] Group 1 - The acquisition will result in Bozhou Trading Center holding 100% of Guizhou Shennong Valley after the transaction is completed [1] - The transaction does not constitute a related party transaction or a major asset restructuring, and therefore does not require approval from the company's board of directors or shareholders' meeting [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of a new herbal medicine, Compound Qilan Oral Solution, aimed at treating children aged 4-12 with external wind-heat symptoms [1] Group 1: Product Development - The Compound Qilan Oral Solution is an independently developed traditional Chinese medicine by the company, derived from the classic formula "Yinqiao San" from the Qing Dynasty [1] - This product is part of the company's respiratory disease medication line and represents one of its key offerings [1] Group 2: Financial Aspects - The projected sales revenue for the Compound Qilan Oral Solution in 2024 is estimated to be 212 million yuan [1] - The company has invested approximately 15 million yuan in research and development for this product to date [1]

Core Viewpoint - The company received a shareholder inquiry letter from the China Securities Investor Service Center regarding compliance with disclosure and approval procedures related to a significant transaction that generated substantial profits exceeding regulatory thresholds [1][2][3]. Group 1: Transaction Details - The company reported a financial net gain of 420 million yuan from a transaction, which represents over 50% of the company's audited net profit of 185 million yuan for 2022 [1][3]. - The transaction's total amount was 425 million yuan, and it was noted that the transaction's profit exceeded the regulatory requirement of 5 million yuan [3]. Group 2: Regulatory Compliance Issues - The company faced scrutiny due to a warning letter from the Heilongjiang Securities Regulatory Bureau, which identified non-operational fund occupation by the controlling shareholder amounting to 80 million yuan, returned in February 2024 [2]. - The company failed to timely disclose and seek shareholder approval for the transaction, which was only addressed in a board meeting held on April 1, 2025, with subsequent disclosure on April 2, 2025 [3]. Group 3: Measures for Improvement - The company has implemented a comprehensive review and revision of its information disclosure management system to ensure compliance with standards, processes, and responsibilities [4]. - Internal controls have been strengthened, emphasizing the importance of compliance with disclosure regulations and enhancing the effectiveness of internal governance [5][6]. - The company has initiated training programs for personnel involved in information disclosure to improve their understanding of legal requirements and enhance compliance awareness [6][7].

关于中证中小投资者服务中心《股东质询函》的 回复公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：603567 证券简称：珍宝岛 公告编号：临 2025-039 黑龙江珍宝岛药业股份有限公司 黑龙江珍宝岛药业股份有限公司（以下简称"公司"）近日收到中证中小投 资者服务中心（以下简称"投服中心"）的《股东质询函》（投服中心行权函【2025】 11 号），投服中心对公司 2023 年 8 月转让子公司股权并于近期补充披露的违规 操作事项提出质询。现就相关问题回复如下： 一、《上海证券交易所股票上市规则》(2023 年 2 月修订)6.1.3 条规定,交 易产生的利润占上市公司最近一个会计年度经审计净利润的 50%以上，且绝对金 额超过 500 万元，上市公司除应当及时披露外，还应当提交股东大会审议。根 据公告披露，本次交易完成后获得财务净收益 4.2 亿元,2022 年，你公司归属于 上市公司股东的净利润为 1.85 亿元,交易产生的利润占最近一个会计年度经审 计净利润的 50%以上，且绝对金额超过 500 万元。 ...

Core Viewpoint - The 90th National Pharmaceutical Trade Fair showcased Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd., highlighting its brand, high-value product matrix, and ecological win-win philosophy [3][4] Group 1: Product Showcase - Zhenbaodao Pharmaceutical exhibited high-quality product lines focusing on cardiovascular, respiratory, and anti-infection treatment areas, including key products like Injection Blood Setong 100mg and Xuechuang Capsule [3] - The company has developed a dual-driven system of "Traditional Chinese Medicine + Chemical Medicine," featuring products such as Compound Qilan Oral Liquid and Injection Ammonium Bromide [3] Group 2: Marketing Strategy - The company emphasized its 2025 "Guangshen Tuo" marketing strategy, which segments regional markets based on product attributes and promotes a model of "recruiting merchants, finding merchants, and servicing merchants" to enhance terminal coverage and sales efficiency [4] - Zhenbaodao Pharmaceutical established a three-tier academic promotion system, integrating medical, market, and data teams to monitor industry trends and provide precise marketing strategies [4] Group 3: Collaborative Ecosystem - The participation in the trade fair demonstrated the company's competitive product pipeline and industrial layout, aiming to build a comprehensive ecosystem of strategic collaboration, resource sharing, and value co-creation [4] - The company plans to continue driving innovation and collaboration, positioning itself to lead the pharmaceutical industry towards higher value creation [4]

Core Points - The company held its 18th meeting of the 5th Supervisory Board on May 13, 2025, where it approved the use of idle raised funds to temporarily supplement working capital [1][2] - The Supervisory Board concluded that the approval process for using up to RMB 300 million of idle raised funds complies with relevant laws and regulations, does not change the purpose of the raised funds, and does not harm shareholder interests [1][2] Summary by Sections Meeting Details - The meeting was conducted in person at the company's conference room with three supervisors present, chaired by Mr. Lan Peibao [1] Resolution Passed - The resolution to use idle raised funds was unanimously approved by the Supervisory Board with three votes in favor and no votes against or abstentions [2]

证券代码：603567 证券简称：珍宝岛 公告编号：临 2025-036 监事会认为：公司本次使用不超过人民币 30,000 万元闲置募集资金暂时补 充流动资金相关审批程序符合《上海证券交易所股票上市规则》《上市公司监管 指引第 2 号——上市公司募集资金管理和使用的监管要求》等相关法律、法规和 规范性文件的规定，未改变募集资金用途，未影响募集资金的投资计划，不存在 损害股东利益的情形，符合公司经营发展需要。公司监事会一致同意本议案。 表决结果：同意 3 票，反对 0 票，弃权 0 票。 具体内容详见同日在上海证券交易所网站（www.sse.com.cn）披露的《黑龙 江珍宝岛药业股份有限公司关于归还募集资金并继续使用部分闲置募集资金暂 时补充流动资金的公告》（公告编号：临 2025-037 号）。 特此公告。 黑龙江珍宝岛药业股份有限公司 第五届监事会第十八次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 黑龙江珍宝岛药业股份有限公司（以下简称"公司"）第五届监事会第十八 次会议于 2025 年 5 月 13 ...

证券代码：603567 证券简称：珍宝岛 公告编号：临 2025-035 黑龙江珍宝岛药业股份有限公司 第五届董事会第二十二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司全资子公司哈尔滨珍宝制药有限公司（以下简称"哈珍宝"）申请银行 贷款展期并由公司为其提供担保事项符合公司整体经营和业务发展需要,符合公 司和全体股东的整体利益。本次担保风险可控,不存在损害公司股东尤其是中小 股东利益的情形，有利于公司整体生产经营的良性发展。董事会同意公司全资子 公司哈珍宝申请期限为一年的贷款展期业务，展期金额为不超过人民币 1.70 亿 元，由公司为哈珍宝本次贷款展期事项提供连带责任担保，并授权公司法定代表 人处理本次担保事项并签署相关协议。 表决结果：同意 5 票，反对 0 票，弃权 0 票。 具体内容详见同日在上海证券交易所网站（www.sse.com.cn）披露的《黑龙 江珍宝岛药业股份有限公司关于为全资子公司银行贷款展期提供担保的公告》 （公告编号：临 2025-038 号）。 特此公告。 黑龙江珍宝岛药业股份有 ...

国新证券股份有限公司关于 黑龙江珍宝岛药业股份有限公司 使用部分闲置募集资金暂时补充流动资金的核查意见 国新证券股份有限公司（以下简称"国新证券"或"保荐机构"）作为黑龙 江珍宝岛药业股份有限公司（以下简称"珍宝岛"或"公司"）2020 年度非公开 发行 A 股股票的保荐机构，根据《中华人民共和国证券法》《证券发行上市保荐 业务管理办法》《上海证券交易所股票上市规则（2025 年 4 月修订）》《上海证券 交易所上市公司自律监管指引第 1 号——规范运作（2023 年 12 月修订）》《上市 公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求（2022 年修 订）》等有关法规和规范性文件的要求，对珍宝岛使用部分闲置募集资金暂时补 充流动资金的事项进行了审慎核查，核查意见如下： 一、募集资金的基本情况 1、募集资金到位及管理与存放情况 经中国证券监督管理委员会出具的《关于核准黑龙江珍宝岛药业股份有限公 司非公开发行股票的批复》（证监许可[2021]338 号）核准，珍宝岛非公开发行人 民币普通股（A 股）92,803,592 股，发行价格为 13.34 元/股，募集资金总额为人 民币 1,237,9 ...

重要内容提示： 黑龙江珍宝岛药业股份有限公司（以下简称"公司"）归还募集资金 23,000 万元，并继续使用部分闲置募集资金临时补充流动资金总额不超过 30,000 万元，使用期限为自公司第五届董事会第二十二次会议和第五届监事会 第十八次会议审议通过之日起不超过 12 个月。 一、募集资金基本情况 1、募集资金到位及管理与存放情况 证券代码：603567 证券简称：珍宝岛 公告编号：临 2025-037 黑龙江珍宝岛药业股份有限公司 关于归还募集资金并继续使用部分闲置募集资金 暂时补充流动资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 经中国证券监督管理委员会出具的《关于核准黑龙江珍宝岛药业股份有限公 司非公开发行股票的批复》（证监许可[2021]338 号）核准，公司非公开发行人 民币普通股（A 股）92,803,592 股，发行价格为 13.34 元/股，募集资金总额为 人民币 1,237,999,917.28 元,扣除本次发行费用人民币 20,759,785.06 元（不含 税）且不包括人民币普通股（A 股） ...